In:
The Kaohsiung Journal of Medical Sciences, Wiley, Vol. 29, No. 7 ( 2013-07), p. 379-384
Kurzfassung:
Different types of proton pump inhibitor (PPI)‐based triple therapies could result in different Helicobacter pylori eradication rates. This study aimed to compare the efficacy and safety of rabeprazole‐ and lansoprazole‐based triple therapies in primary treatment of H. pylori infection. From September 2005 to July 2008, 426 H. pylori ‐infected patients were randomly assigned to receive a 7‐day eradication therapy with either rabeprazole 20 mg bid (RAC group, n = 222) or lansoprazole 30 mg bid (LAC group, n = 228) in combination with amoxicillin 1 g bid and clarithromycin 500 mg bid. The patients received follow‐up esophagogastroduodenoscopy (EGD) and/or 13 C‐urea breath test 12–16 weeks later to define H. pylori status. Their personal and medical history, compliance and side effects were obtained by using a standardized questionnaire. Intention‐to‐treat analysis revealed that the eradication rate was 87.84% in the RAC group and 85.96% in the LAC group ( p = 0.56). All patients returned for assessment of compliance (100% in the LAC group vs. 99.50% in the RAC group; p = 0.32) and adverse events (7.20% in the RAC group vs. 5.70% in the LAC group, p = 0.51). Univariate analysis suggested that patients with nonsteroid anti‐inflammatory agent (NSAID) use had lower eradication rates than those without (76.71% vs. 88.74%; p = 0.006). Our results showed that efficacy and safety were similar in rabeprazole‐ and lansoprazole‐based primary therapies. The influence of NSAID usage on H. pylori eradication needs to be further investigated.
Materialart:
Online-Ressource
ISSN:
1607-551X
,
2410-8650
DOI:
10.1016/j.kjms.2012.11.006
Sprache:
Englisch
Verlag:
Wiley
Publikationsdatum:
2013
ZDB Id:
2202782-8
Bookmarklink